Format
Sort by
Items per page

Send to

Choose Destination

See Gene information for atm chek2

atm in Homo sapiens (2)Mus musculus (2)Rattus norvegicus (2)All 274 Gene records

chek2 in Homo sapiens (2)Mus musculus (2)Rattus norvegicus (2)All 269 Gene records

Search results

Items: 1 to 20 of 683

1.

Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death.

van Harten AM, Buijze M, van der Mast R, Rooimans MA, Martens-de Kemp SR, Bachas C, Brink A, Stigter-van Walsum M, Wolthuis RMF, Brakenhoff RH.

Oncogenesis. 2019 Jun 17;8(7):38. doi: 10.1038/s41389-019-0147-x.

PMID:
31209198
2.

Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.

Weitzel JN, Neuhausen SL, Adamson A, Tao S, Ricker C, Maoz A, Rosenblatt M, Nehoray B, Sand S, Steele L, Unzeitig G, Feldman N, Blanco AM, Hu D, Huntsman S, Castillo D, Haiman C, Slavin T, Ziv E.

Cancer. 2019 Jun 17. doi: 10.1002/cncr.32083. [Epub ahead of print]

PMID:
31206626
3.

The Spectrum of Mutations Predisposing to Familial Breast Cancer in Poland.

Cybulski C, Kluźniak W, Huzarski T, Wokołorczyk D, Kashyap A, Rusak B, Stempa K, Gronwald J, Szymiczek A, Bagherzadeh M, Jakubowska A, Dębniak T, Lener M, Rudnicka H, Szwiec M, Jarkiewicz-Tretyn J, Stawicka M, Domagała P, Narod SA, Lubiński J, Akbari MR; Polish Hereditary Breast Cancer Consortium.

Int J Cancer. 2019 Jun 7. doi: 10.1002/ijc.32492. [Epub ahead of print]

PMID:
31173646
4.

Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers.

Nones K, Johnson J, Newell F, Patch AM, Thorne H, Kazakoff SH, de Luca XM, Parsons MT, Ferguson K, Reid L, McCart Reed AE, Srihari S, Lakis V, Davidson AL, Mukhopadhyay P, Holmes O, Xu Q, Wood S, Leonard C; Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab); Australian Breast Cancer Tissue Bank (ABCTB); Brisbane Breast Bank (BBB), Beesley J, Harris J, Barnes D, Degasperi A, Ragan MA, Spurdle AB, Khanna KK, Lakhani SR, Pearson JV, Nik-Zainal S, Chenevix-Trench G, Waddell N, Simpson PT.

Ann Oncol. 2019 May 15. pii: mdz132. doi: 10.1093/annonc/mdz132. [Epub ahead of print]

PMID:
31090900
5.

Germline and Somatic Mutations in Prostate Cancer for the Clinician.

Cheng HH, Sokolova AO, Schaeffer EM, Small EJ, Higano CS.

J Natl Compr Canc Netw. 2019 May 1;17(5):515-521. doi: 10.6004/jnccn.2019.7307. Review.

PMID:
31085765
6.

Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing.

Slavin TP, Coffee B, Bernhisel R, Logan J, Cox HC, Marcucci G, Weitzel J, Neuhausen SL, Mancini-DiNardo D.

Cancer Genet. 2019 Apr 13. pii: S2210-7762(18)30555-6. doi: 10.1016/j.cancergen.2019.04.005. [Epub ahead of print]

PMID:
31056428
7.

Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.

Parikh AR, He Y, Hong TS, Corcoran RB, Clark JW, Ryan DP, Zou L, Ting DT, Catenacci DV, Chao J, Fakih M, Klempner SJ, Ross JS, Frampton GM, Miller VA, Ali SM, Schrock AB.

Oncologist. 2019 Apr 30. pii: theoncologist.2019-0034. doi: 10.1634/theoncologist.2019-0034. [Epub ahead of print]

PMID:
31040255
8.

Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms.

Bernstein-Molho R, Singer A, Laitman Y, Netzer I, Zalmanoviz S, Friedman E.

Breast Cancer Res Treat. 2019 Jul;176(1):165-170. doi: 10.1007/s10549-019-05228-6. Epub 2019 Apr 12.

PMID:
30980208
9.

Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.

Kurian AW, Ward KC, Howlader N, Deapen D, Hamilton AS, Mariotto A, Miller D, Penberthy LS, Katz SJ.

J Clin Oncol. 2019 May 20;37(15):1305-1315. doi: 10.1200/JCO.18.01854. Epub 2019 Apr 9.

PMID:
30964716
10.

Prevalence of germline variants in inflammatory breast cancer.

Rana HQ, Sacca R, Drogan C, Gutierrez S, Schlosnagle E, Regan MM, Speare V, LaDuca H, Dolinsky J, Garber JE, Overmoyer BA.

Cancer. 2019 Apr 1. doi: 10.1002/cncr.32062. [Epub ahead of print]

PMID:
30933323
11.

Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels.

Feliubadaló L, López-Fernández A, Pineda M, Díez O, Del Valle J, Gutiérrez-Enríquez S, Teulé A, González S, Stjepanovic N, Salinas M, Capellá G, Brunet J, Lázaro C, Balmaña J; Catalan Hereditary Cancer Group.

Int J Cancer. 2019 Mar 29. doi: 10.1002/ijc.32304. [Epub ahead of print]

PMID:
30927264
12.

Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.

Nurmi A, Muranen TA, Pelttari LM, Kiiski JI, Heikkinen T, Lehto S, Kallioniemi A, Schleutker J, Bützow R, Blomqvist C, Aittomäki K, Nevanlinna H.

Int J Cancer. 2019 Mar 30. doi: 10.1002/ijc.32309. [Epub ahead of print]

PMID:
30927251
13.

DNA damage as a marker of brain damage in individuals with history of concussions.

Schwab N, Tator C, Hazrati LN.

Lab Invest. 2019 Feb 13. doi: 10.1038/s41374-019-0199-8. [Epub ahead of print]

PMID:
30760862
14.

Detection of Pathogenic Germline Variants Among Patients With Advanced Colorectal Cancer Undergoing Tumor Genomic Profiling for Precision Medicine.

You YN, Borras E, Chang K, Price BA, Mork M, Chang GJ, Rodriguez-Bigas MA, Bednarski BK, Meric-Bernstam F, Vilar E.

Dis Colon Rectum. 2019 Apr;62(4):429-437. doi: 10.1097/DCR.0000000000001322.

PMID:
30730459
15.

Bringing Prostate Cancer Germline Genetics into Clinical Practice.

Das S, Salami SS, Spratt DE, Kaffenberger SD, Jacobs MF, Morgan TM.

J Urol. 2019 Feb 5:101097JU0000000000000137. doi: 10.1097/JU.0000000000000137. [Epub ahead of print]

PMID:
30730411
16.

Diagnostic yield and clinical utility of a comprehensive gene panel for hereditary tumor syndromes.

Henn J, Spier I, Adam RS, Holzapfel S, Uhlhaas S, Kayser K, Plotz G, Peters S, Aretz S.

Hered Cancer Clin Pract. 2019 Jan 23;17:5. doi: 10.1186/s13053-018-0102-4. eCollection 2019.

17.

Genetic analysis of subsequent second primary malignant neoplasms in long-term pancreatic cancer survivors suggests new potential hereditary genetic alterations.

Lovecek M, Janatova M, Skalicky P, Zemanek T, Havlik R, Ehrmann J, Strouhal O, Zemankova P, Lhotova K, Borecka M, Soukupova J, Svebisova H, Soucek P, Hlavac V, Kleibl Z, Neoral C, Melichar B, Mohelnikova-Duchonova B.

Cancer Manag Res. 2019 Jan 10;11:599-609. doi: 10.2147/CMAR.S185352. eCollection 2019.

18.

Cytostatic and Anti-tumor Potential of Ajwa Date Pulp against Human Hepatocellular Carcinoma HepG2 Cells.

Siddiqui S, Ahmad R, Khan MA, Upadhyay S, Husain I, Srivastava AN.

Sci Rep. 2019 Jan 21;9(1):245. doi: 10.1038/s41598-018-36475-0.

19.

BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors.

Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, Hartley S, Babb de Villiers C, Izquierdo A, Simard J, Schmidt MK, Walter FM, Chatterjee N, Garcia-Closas M, Tischkowitz M, Pharoah P, Easton DF, Antoniou AC.

Genet Med. 2019 Jan 15. doi: 10.1038/s41436-018-0406-9. [Epub ahead of print] Erratum in: Genet Med. 2019 Feb 21;:.

PMID:
30643217
20.

The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.

Hjortkjær M, Malik Aagaard Jørgensen M, Waldstrøm M, Ørnskov D, Søgaard-Andersen E, Jakobsen A, Dahl-Steffensen K.

Int J Gynecol Cancer. 2019 Jan;29(1):166-173. doi: 10.1136/ijgc-2018-000017.

PMID:
30640700

Supplemental Content

Loading ...
Support Center